Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially.

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Takahiro.

How to Treat MDS without Stem Cell Transplantation

Kidney and Bladder Outcomes in Children with Hemorrhagic Cystitis and BK Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation Benjamin.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.

Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is.

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children Matthias Eyrich, Gernot.

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte.

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Immunologic Resolution of Human Chronic Graft-versus-Host Disease

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities Juliet N. Barker, Courtney E.

B Cells and Transplantation: An Educational Resource

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation Eleshia J. Morrison, Shawna L. Ehlers,

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation

Pauline Damien, David S. Allan

What is quality in a transplant program?

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Richard Mitchell, John E. Wagner, Claudio G

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children Xiaojun.

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

T Cell–Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano, Shelly Heimfeld, Ted Gooley,

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

Presentation transcript:

Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially T Cell–Depleted Peripheral Blood Stem Cells and Umbilical Cord Blood Benjamin R. Oshrine, Yimei Li, David T. Teachey, Jennifer Heimall, David M. Barrett, Nancy Bunin Biology of Blood and Marrow Transplantation Volume 19, Issue 11, Pages 1581-1589 (November 2013) DOI: 10.1016/j.bbmt.2013.08.003 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Levels of NK cells (A), total lymphocytes (B), and T cells (C) as a function of time after HSCT, by graft type. All lymphocyte numbers have been logarithmically transformed and are presented as mean with 95% CI error bars. P values based on linear mixed-effect modeling: ∗P < .001; #P < .01; ˆP < .05. Biology of Blood and Marrow Transplantation 2013 19, 1581-1589DOI: (10.1016/j.bbmt.2013.08.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Levels of CD4+ T cells (A), cytotoxic T cells (B), naïve CD4+ T cells (C), and memory CD4+ T cells (D), and 4:8 ratio and RA:RO ratio as a function of time after HSCT (E), by graft type. All lymphocyte numbers have been logarithmically transformed and are presented as means with 95% CI error bars. 4:8 and RA:RO are untransformed and presented as mean with SEM error bars. P values based on linear mixed-effect modeling: ∗P < .001; #P < .01; ˆP < .05. Biology of Blood and Marrow Transplantation 2013 19, 1581-1589DOI: (10.1016/j.bbmt.2013.08.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Levels of B cells (A), IgM (B), and IgA (C) as a function of time after transplant, by graft type. All lymphocyte numbers have been logarithmically transformed and are presented as means with 95% CI error bars. P values based on linear mixed-effect modeling: ∗P < .001; #P < .01; ˆP < .05. Biology of Blood and Marrow Transplantation 2013 19, 1581-1589DOI: (10.1016/j.bbmt.2013.08.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Responses to mitogen stimulation based on graft time by time after HSCT, by graft type. (A) PHA. (B) PWM. (C) ConA. Data are presented as mean CPMrel with SEM error bars. No significant between-group differences were detected. Biology of Blood and Marrow Transplantation 2013 19, 1581-1589DOI: (10.1016/j.bbmt.2013.08.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Levels of CD4+ T cells (A), naïve CD4+ T cells (B), and B cells (C) as a function of time after HSCTon, by cGVHD status. All lymphocyte numbers have been logarithmically transformed, and are represented as means with 95% CI error bars. P values based on linear mixed-effect modeling: ∗P < .001; #P < .01; ˆP < .05. Biology of Blood and Marrow Transplantation 2013 19, 1581-1589DOI: (10.1016/j.bbmt.2013.08.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions